Former CoLucid Drug, Lasmiditan, Receives FDA Approval
INDIANAPOLIS, Oct. 11, 2019 — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists).
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.